Table 4.

Use of Nielsen criteria as a surrogate for basal-like breast cancer

ERHER2CK5/6EGFRBest response
Patient 10%1+0%0%POD < 3 mo
Patient 20%00%0%SD > 6 mo
Patient 30%010%10%POD 3 mo
Patient 40%025%<10%POD 3 mo

NOTE: Absence of basal-like markers may correlate with response to antiandrogen therapy.